Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lightbody ED"'
Autor:
Tahri S; Dana-Farber Cancer Institute, United States., Piccinelli S; Dana-Farber Cancer Institute, Boston, Massachusetts, Netherlands., Su NK; Harvard Medical School, United States., Lampe LM; Christian-Albrechts University, Germany., Dong H; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Vergara Cadavid J; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Boiarsky R; CSAIL, United States., Papazian N; Erasmus MC, Rotterdam, Netherlands., Lightbody ED; Harvard Medical School, United States., Cao A; Harvard Medical School, United States., Alberge JB; Harvard Medical School, United States., Ferrari de Andrade L; Icahn School of Medicine at Mount Sinai, New York, New York, United States., Rahmat M; Harvard Medical School, United States., Shen Y; Cancer Science Institute of Singapore, Singapore., Blanco Fernández L; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Zabaleta A; Cancer Center Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), Pamplona, Spain., Guenther A; Christian-Albrechts University, Kiel, Germany., Getz G; Broad Institute, Mass General Hospital, Cambridge, Massachusetts, United States., Sonneveld P; Erasmus MC Cancer Institute Rotterdam, Rotterdam, Netherlands., Cupedo T; Erasmus University Medical Center, Rotterdam, Netherlands., Wucherpfennig KW; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Ghobrial IM; Harvard Medical School, United States., Romee R; Harvard Medical School, United States.
Publikováno v:
Blood advances [Blood Adv] 2024 Aug 06. Date of Electronic Publication: 2024 Aug 06.
Autor:
Nadeem O; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Aranha MP; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Redd R; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Timonian M; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Magidson S; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lightbody ED; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Alberge JB; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Bertamini L; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dutta AK; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., El-Khoury H; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bustoros M; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-Presbyterian Hospital, New York, New York, USA., Laubach JP; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bianchi G; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., O'Donnell E; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wu T; Broad Institute, Boston, MA, USA., Tsuji J; Broad Institute, Boston, MA, USA., Anderson K; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Broad Institute, Boston, MA, USA., Trippa L; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Richardson PG; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sklavenitis-Pistofidis R; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute, Boston, MA, USA., Ghobrial IM; Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Publikováno v:
MedRxiv : the preprint server for health sciences [medRxiv] 2024 Apr 19. Date of Electronic Publication: 2024 Apr 19.
Autor:
Sklavenitis-Pistofidis R; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece., Lightbody ED; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Reidy M; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tsuji J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Aranha MP; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Huynh D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chong SJF; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hackett L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Haradhvala NJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Wu T; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Berrios B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Alberge JB; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dutta A; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Davids MS; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Papaioannou M; Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.; Hematology Unit, 1st Internal Medicine Department, AHEPA University Hospital, Thessaloniki, Greece., Getz G; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Ghobrial IM; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000, France.; Department of Hematology, CHU Lille, Lille University, 59000, France.
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2023 Aug 03. Date of Electronic Publication: 2023 Aug 03.
Autor:
Shakfa N; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Li D; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Conseil G; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Lightbody ED; Dana-Farber Cancer Institute, Harvard University, Cambridge, Massachusetts, USA., Wilson-Sanchez J; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Hamade A; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Chenard S; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada., Jawa NA; Centre for Neuroscience Studies & School of Medicine, Queen's University, Kingston, Ontario, Canada., Laight BJ; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.; Pathology and Molecular Medicine, Queen's University Cancer Research Institute, Kingston, Ontario, Canada., Afriyie-Asante A; Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Tyryshkin K; Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada., Koebel M; Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada., Koti M; Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada kotim@queensu.ca.; Queen's Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Apr; Vol. 11 (4).
Autor:
Dutta AK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Alberge JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Lightbody ED; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Boehner CJ; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Dunford A; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Mouhieddine TH; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Cowan AN; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Su NK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Horowitz EM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Barr H; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Hevenor L; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Beckwith JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Perry J; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Cao A; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Lin Z; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Kuhr FK; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Mastro RGD; Menarini Silicon Biosystems, Huntingdon Valley, Pennsylvania., Nadeem O; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts., Greipp PT; Department of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota., Stewart C; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts., Auclair D; Multiple Myeloma Research Foundation, Norwalk, Connecticut., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
Publikováno v:
Cancer discovery [Cancer Discov] 2023 Feb 06; Vol. 13 (2), pp. 348-363.
Autor:
Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aranha MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Redd RA; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Baginska J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haradhvala NJ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Graduate Program in Biophysics, Harvard University, Cambridge, MA 02138, USA., Hallisey M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dutta AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Savell A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Varmeh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Heilpern-Mallory D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Ujwary S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Zavidij O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Aguet F; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Bustoros M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Mouhieddine TH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Wu T; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Flechon L; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France., Anand S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Rosenblatt JM; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA., Zonder J; Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA., Vredenburgh JJ; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Boruchov A; St. Francis Hospital and Cancer Center, Hartford, CT 06105, USA., Bhutani M; Levine Cancer Institute, Charlotte, NC 28204, USA., Usmani SZ; Levine Cancer Institute, Charlotte, NC 28204, USA., Matous J; Colorado Blood Cancer Institute, Denver, CO 80218, USA., Yee AJ; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA., Jakubowiak A; University of Chicago Cancer Center, Chicago, IL 60637, USA., Laubach J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Manier S; INSERM UMRS1277, CNRS UMR9020, Lille University, 59000 Lille, France; Department of Hematology, CHU Lille, Lille University, 59000 Lille, France., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA., Badros AZ; University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA., Mateos MV; University Hospital of Salamanca - Instituto de Investigación Biomédica de Salamanca, 37007 Salamanca, Spain., Trippa L; Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Getz G; Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: gadgetz@broadinstitute.org., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02115, USA; Center for Prevention of Progression (CPOP), Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Cancer cell [Cancer Cell] 2022 Nov 14; Vol. 40 (11), pp. 1358-1373.e8.
Autor:
El-Khoury H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lee DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Cea-Curry CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Barr H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Murphy C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sakrikar D; The Binding Site, Rochester, MN, USA., Barnidge D; The Binding Site, Rochester, MN, USA., Bustoros M; Department of Medical Oncology, Weill Cornell Medicine, New York, NY, USA., Leblebjian H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA., Cowan A; Alix School of Medicine, The Mayo Clinic, Rochester, MN, USA., Davis MI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Amstutz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Boehner CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Perkins MC; The Binding Site Group, Birmingham, UK., Harding S; The Binding Site Group, Birmingham, UK., Mo CC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Kapoor P; The Mayo Clinic, Rochester, MN, USA., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA; International Myeloma Foundation, North Hollywood, CA, USA., Borrello IM; Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Fonseca R; Department of Medical Oncology, The Mayo Clinic, Phoenix, AZ, USA., Weiss ST; Harvard Medical School, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Karlson E; Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Trippa L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rebbeck TR; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Harvard Medical School, Boston, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Center for Prevention of Progression of Blood Cancer, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.
Publikováno v:
The Lancet. Haematology [Lancet Haematol] 2022 May; Vol. 9 (5), pp. e340-e349. Date of Electronic Publication: 2022 Mar 25.
Autor:
Dutta AK; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Alberge JB; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sklavenitis-Pistofidis R; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lightbody ED; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Ghobrial IM; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Department of Medical Oncology, Harvard Medical School, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2022 Apr; Vol. 19 (4), pp. 223-236. Date of Electronic Publication: 2022 Jan 11.
Autor:
Hallisey M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Dennis J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Abrecht C; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Pistofidis RS; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Schork AN; Longwood Medical Area CyTOF Core, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lightbody ED; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Heilpern-Mallory D; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Severgnini M; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Ghobrial IM; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hodi FS; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA., Baginska J; Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Publikováno v:
STAR protocols [STAR Protoc] 2022 Feb 17; Vol. 3 (1), pp. 101163. Date of Electronic Publication: 2022 Feb 17 (Print Publication: 2022).
Autor:
Konishi Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Sklavenitis-Pistofidis R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Yue H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ferrari F; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Redd RA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Russo M; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Horowitz E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Justis AV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Shayegh NA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Savell A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Prescott J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Varmeh S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Hamilton M; Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA., Auclair D; Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, USA., Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Trippa L; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Electronic address: irene_ghobrial@dfci.harvard.edu.
Publikováno v:
Cancer cell [Cancer Cell] 2022 Jan 10; Vol. 40 (1), pp. 6-8. Date of Electronic Publication: 2021 Dec 09.